Thursday, September 2, 2010 10:23:03 AM EDT
Show Me
|

ARYx Therapeutics IncNASDAQ:ARYX*

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Change company  Symbol lookup
ARYXARYx Therapeutics Inc
IDIXIdenix Pharmaceuticals Inc
DPZDomino's Pizza Inc
PDLIPDL BioPharma Inc
Healthcare : Biotechnology & Drugs
$0.3899 
 
 0.0001 (0.03%)        
Bid
--
Ask
--
B/A Size
--
High
0.39
Low
0.3899
Volume
8,300 (Below Avg)
  • Overview
  • News
  • Charts
  • Earnings
  • Fundamentals
  • Valuation
  • Calendar
  • Reports
  • SEC Filings

0.39

13.0M


0.39

33.5M


0.3899 - 0.39

-0.83


169.8K

--


9:52a ET 09/02/10

No Regular Dividends


1.8K

--


Low
High

--


10.83%

12


0.0%

0.35


103.1%

Historical Quotes & Splits
 

Current|1mo|3mo|6mo|1yr
DJIA
S&P 500
NASDAQ
SMA(50)
View Advanced Chart
  • News
  • Industry Position
  • Company Profile

August 16, 2010

7:00a
ARYx Therapeutics Secures Interim Financing(Business Wire)

March 29, 2010

4:26p
Monday's biggest gaining and declining stocks(MarketWatch)

February 19, 2010

4:47p
Friday's biggest gaining and declining stocks(MarketWatch)
Go to All Current & Historical News
Events
08/16/2010
Q2 2010 ARYx Therapeutics Inc Earnings Release - Estimate: $-0.11
05/13/2010
Q1 2010 ARYx Therapeutics Inc Earnings Release - Estimate: $-0.22
03/29/2010
Q4 2009 ARYx Therapeutics Inc Earnings Release - Estimate: $-0.21
11/12/2009
Q3 2009 ARYx Therapeutics Inc Earnings Release - Estimate: $-0.30
More Calendar Events
Market data accompanied by       is delayed by at least 15 minutes for NASDAQ, AMEX, NYSE and Options. Duration of the delay for other exchanges vary.
Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Market data provided by 

Information provided by 
, 
Computrade Systems, Inc., 
 , 
News provided by: 
and 

Copyright ©2010. All rights reserved.


3rd Party Research Disclosure /public-10:19:28

Market Data Disclosure